Glenmark USA settles antitrust suits for $29.628 million

Glenmark Pharmaceuticals Limited has announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to a settlement agreement to resolve multiple antitrust lawsuits. The disclosure was made to the stock exchanges on May 23, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The litigation involved allegations of price-fixing, market allocation, and related anti-competitive conduct regarding generic pharmaceutical products. Since 2016, Glenmark USA had been named in more than 35 complaints consolidated in the Eastern District of Pennsylvania, U.S. The plaintiffs included direct purchasers, end-payers, indirect purchasers, and 46 state attorneys general. Three complaints filed by state attorneys general were transferred to the District of Connecticut in 2024.

Settlement Terms

To resolve the dispute and avoid uncertainty, Glenmark USA has agreed to pay a total amount of $29.628 million. The payment will be made in annual instalments over a period of five years. The agreement is subject to approval by the court overseeing the litigation.

Settlement Detail	Amount / Terms
Total Settlement Amount	$29.628 million
Payment Structure	Annual instalments over 5 years
Status	Subject to court approval

The company explicitly stated that Glenmark USA denies each and every allegation made against it. The settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of the subsidiary.

Financial Impact

Glenmark Pharmaceuticals Limited confirmed that the full amount of the payments under the settlement agreements has been provided for in its financials. Consequently, the company stated that this settlement will not have a significant impact on its financial position.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.00%	-0.91%	-7.27%	+8.62%	+28.12%	+236.51%

Glenmark Pharmaceuticals ' biotech arm, Ichnos Glenmark Innovation (IGI), has introduced ISB 2301, a first-in-class, multispecific immune cells activator designed for the potential treatment of multiple solid tumor indications. The announcement marks a significant advancement in the venture's oncology pipeline, leveraging its proprietary BEAT® technology platform to address the biological complexity of solid tumors.

ISB 2301: A Multispecific Immune Cells Activator

ISB 2301 is a next-generation multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death. It engages both T cells and natural killer (NK) cells to ignite the immune system, offering a multi-mechanistic approach to cancer treatment. The candidate is classified as a first-in-class molecule, designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and a sustained type 1 immune response.

Parameter	Details
Candidate Name	ISB 2301
Classification	First-in-Class Multispecific Immune Cells Activator
Target Indication	Multiple Solid Tumors
Mechanism	Targets 3 Tumor-Associated Antigens; Activates T and NK Cells
Introduced By	IGI (Biotech arm of Glenmark Pharmaceuticals)

Strategic Development and Clinical Plans

The development of ISB 2301 was enabled by IGI's clinically validated BEAT® platform, which allows for manufacturing with a standard multispecific antibody process. Preclinical data indicates that ISB 2301 demonstrates excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates. Building on the platform's success, IGI intends to submit an Investigational New Drug (IND) application for ISB 2301 by the end of this year, with clinical studies scheduled to begin in 2027.